Lovastatin has been available for prescription use in the United States for about 20 months
(as of June 1989). Over 1 million patients have received the prescription drug, and …

Objectives To compare the safety and efficacy of lovastatin and simvastatin in patients with
primary hypercholesterolemia. Methods Fourteen Canadian centres participated in this …

The efficacy, safety and tolerability of simvastatin 10 mg/day and pravastatin 20 mg/day were
compared in this multinational double-blind randomised parallel trial involving 273 patients …

Objective: To study the long-term efficacy and safety of the cholesterol synthesis inhibitor,
simvastatin, in the treatment of familial hypercholesterolaemia. Methods: This is an open …

Background: Elevated levels of low‐density lipoprotein (LDL) cholesterol promote the
development of atherosclerosis and coronary heart disease. Hypothesis: Simvastatin 80 …

Fluvastatin monotherapy up to 40 mg/day over 52 weeks in patients with primary
hypercholesterolemia decreased plasma low density lipoprotein cholesterol (LDL-C) by …

Background Although the effectiveness of statins is well established, analyses of
spontaneous adverse event reports have recently questioned the safety of rosuvastatin …

The objective of this multicenter, randomized, open-label, parallel-group, 8-week study was
to evaluate the comparative dose efficacy of the 3-hydroxy-3-methylglutaryl coenzyme A …

The efficacy of lovastatin, a potent inhibitor of HMG CoA reductase, has been established by
numerous studies. At doses of 40 mg administered twice daily, lovastatin produces a mean …

Abstract▴ Rosuvastatin is a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase
inhibitor used in the treatment of patients with dyslipidaemia. Rosuvastatin is not extensively …